阿斯利康与Janssen在日本联合推广Zytiga（abiraterone acetate，醋酸阿比特龙）
- AstraZeneca2013年10月16日 9:45 点击：2109
阿斯利康（AstraZeneca）2013年10月11日宣布，已与强生（JNJ）旗下杨森（Janssen）达成了一项协议，在日本联合推广Zytiga（abiraterone acetate，醋酸阿比特龙），该药是一种创新的口服药物，用于前列腺癌患者的治疗。
AstraZeneca enters co-promotion agreement with Janssen in Japan for innovative prostate cancer treatment
Friday, 11 October 2013
AstraZeneca today announced that it has entered into an agreement with Janssen Pharmaceuticals K. K. in Japan to co-promote abiraterone acetate, an innovative oral therapy for the treatment of patients with prostate cancer.
Currently the main treatment option available to patients in Japan is medical castration, however prostate cancer can still progress in many patients because androgens are produced in other tissues. Abiraterone acetate, a CYP17-inhibitor, inhibits the key enzyme which modulates the production of androgens, hormones which stimulate prostate cancer cells to grow, from all sources in the body. This helps lower the level of androgens available to the prostate cancer cells, which is the goal of treatment in prostate cancer.
Janssen Pharmaceuticals K.K. submitted a marketing approval application for abiraterone acetate to the Japanese Ministry of Health, Labour and Welfare in July 2013 for the treatment of prostate cancer. The product was approved in the US by the Food and Drug Administration in April 2011, and in the EU by the European Commission in September 2011 for the treatment of patients with metastatic castration-resistant prostate cancer.
Marc Dunoyer, Executive Vice President, Global Products and Portfolio Strategy at AstraZeneca said: “Japan is one of the fastest growing pharmaceutical markets, where AstraZeneca has a proven track record of successfully developing and marketing innovative medicines. Abiraterone acetate is a great addition to our existing portfolio of leading cancer treatments, with real potential to address an important and growing patient need. This deal is a strong strategic fit for AstraZeneca, reinforcing both our focus on oncology as a core therapy area and Japan as one of our key growth drivers.”
Financial terms of the agreement were not disclosed.
NOTES TO EDITORS
About abiraterone acetate
Abiraterone acetate is indicated in the US and the EU for the treatment of patients with metastatic castration-resistant prostate cancer in combination with prednisone (steroid) before and after treatment with docetaxel (chemotherapy). Abiraterone acetate has been approved in 83 countries.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
全年征稿 / 资讯合作
联系邮箱：kefu@labbase.net
版权与免责声明
- 凡本网注明“来源：来宝网”的所有作品，版权均属于来宝网，转载请必须注明来宝网， //www.next-search.com，违反者本网将追究相关法律责任。
- 本网转载并注明自其它来源的作品，目的在于传递更多信息，并不代表本网赞同其观点或证实其内容的真实性，不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时，必须保留本网注明的作品来源，并自负版权等法律责任。
- 如涉及作品内容、版权等问题，请在作品发表之日起一周内与本网联系，否则视为放弃相关权利。
